arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Cogent Biosciences, Inc.

COGT

$42.36 ▲ +0.58 (+1.39%) at close

10 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Cogent Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.5B

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -30.6% ↗

FCF / Share $-2.06 ↘

Trailing P/E —

Price / Book 10.7x

FCF Yield —

Debt / Equity 0.35

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$7.87M

↓ -65.0% —

Net Income Profit after all expenses

$-328.94M

↓ -28.6% —

Operating Margin Operating profit as % of sales

-143.0%

↑ +61.3% —

FCF / Share Free cash flow per share

$-2.06

↓ -2.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	—	-65.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-913%)	131.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1539%)	16.4% Good Good Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+105%)	—	—
EPS Growth YoY (%)	-11.3% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	0.0% Caution ↑ Caution Improving Year-over-year change in earnings per share Optimal: > 10%	18.8% Good Good Year-over-year change in earnings per share Optimal: > 10%	-27.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-28.6% Weak ↑ Weak Improving Year-over-year change in net income	-33.0% Weak ↑ Weak Improving Year-over-year change in net income	-37.2% Weak ↑ Weak Improving Year-over-year change in net income	-94.0% Weak ↓ Weak Declining Year-over-year change in net income	3.4% Caution ↑ Caution Improving Year-over-year change in net income	-135.0% Weak ↓ Weak Declining Year-over-year change in net income	7.8% Fair Fair Year-over-year change in net income	-35.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-2.9% Weak ↑ Weak Improving Year-over-year change in free cash flow	-2.2% Weak ↑ Weak Improving Year-over-year change in free cash flow	8.1% Fair Fair Year-over-year change in free cash flow	-36.8% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—
Revenue CAGR 3Y (%)	—	—	—	—	—	-2.0% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	—	-143.0% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1053%)	-369.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2566%)	-312.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2185%)	—
Profit Margin (%) (%)	—	—	—	—	—	—	-141.5% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1279%)	-354.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3056%)	-304.9% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2641%)	—
FCF Margin (%) (%)	—	—	—	—	—	-455.5% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-184.7% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-339.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-319.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.48x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.31x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.05x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-30.6% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-85.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-63.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-45.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-27.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-27.7% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-80.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-47.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	42.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-35.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-84.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-66.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-49.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-32.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-65.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-41.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-53.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-51.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-445%)	-99.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-766%)	-74.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-598%)	-54.8% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-466%)	-33.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-325%)	-31.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-313%)	-100.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-768%)	-57.3% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-482%)	52.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+248%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Debt to Equity (x)	0.35x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-42%)	—	—	—	—	—	—	—	—	—
Interest Coverage (x)	-165.44x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—
Net Debt (USD)	$-89.12M	$-98.17M	$-53.23M	$-139.89M	$-219.68M	$-242.19M	$-37.42M	$-55.67M	$-28.27M	—
Debt / EBITDA (x)	-0.67x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Basic EPS, GAAP (USD)	$-2.16	$-1.94	$-1.94	$-2.39	$-1.87	—	—	—	—	—
Free Cash Flow per Share (USD)	$-2.06	$-2.01	$-1.96	$-2.14	$-1.56	—	—	—	—	—
Book Value per Share (USD)	$3.95	$2.32	$2.99	$3.66	$4.89	$7.25	$4.14	$2.00	$-4.79	—
Tangible Book Value per Share (USD)	$3.95	$2.32	$2.99	$3.66	$4.89	$7.25	$4.14	$2.00	$-4.79	—
Basic Weighted Avg Shares (shares)	128.90M	103.86M	79.66M	58.74M	38.73M	—	—	—	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$846.40M	$240.76M	$232.60M	$238.12M	$205.56M	$231.82M	$27.34M	$56.06M	$31.19M	—
LT Debt (USD)	$222.90M	—	—	—	—	—	—	—	—	—
Total Equity (USD)	$636.37M	$256.29M	$257.80M	$255.74M	$214.18M	$234.67M	$31.76M	$60.23M	$-48.85M	$-24.70M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	$7.87M	$22.50M	$9.73M	$8.36M	—
Depreciation Expense (USD)	$2.56M	$2.45M	$2.27M	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-328.94M	$-255.86M	$-192.41M	$-140.24M	$-72.27M	$-74.81M	$-31.83M	$-34.53M	$-25.49M	—
Operating Cash Flow (USD)	$-264.44M	$-207.79M	$-153.62M	$-118.64M	$-58.76M	$-35.85M	$-41.51M	$-32.49M	$-25.84M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters

Cogent Biosciences, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare COGT with peers